Fewer than one in 10 people who could benefit from obesity jabs such as Wegovy are able to get them, caution the World Health Organization as it issues its initial advice on the medications.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is calling for broader and more equitable access to this class of drugs.
According to estimates, over two billion will be living with obesity by 2030 without intervention.
"The new guidance acknowledges that obesity is a long-term condition that can be treated with thorough and ongoing support," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are major obstacles to widespread availability to the treatments that can help people shift substantial body mass, says the body.
GLP-1 Therapy Supply Crisis
Despite the current most favorable scenario, the production of these medications could only cover about 100 million people – fewer than 10% of eligible patients, according to the health organization.
The recommendation urges nations and manufacturers to widen access, by measures like patent sharing.
A patent on semaglutide – the core ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.
The Way Obesity Jabs Work
The injections imitate a biological compound to delay gastric emptying, curb appetite and increase satiety so users reduce food intake.
Individuals commonly begin shedding pounds within a few weeks of commencing the once-weekly jabs.
Evidence points to people may put most of the weight back on after a year of halting the drug, as their normal food cravings come back.
To be carrying excess weight elevates your likelihood for contracting health problems, like diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight concerns people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, as per the WHO.
